ICH M7
RDC 53
Skin Sensitisation
AI/PDE
Aromatic Amines
Elemental Impurities
Excipients
Intermediates
Nitrites in Excipients
LCDB
About Us: Developing expert computer systems and facilitating data-sharing in the life science industries
We accelerate the discovery pipeline of the life sciences industry by enabling scientifically robust decisions to be made faster through advanced analytics which are informed by our position as the industry’s honest broker.
Products and Initiatives
State-of-the-art computer software for the advancement and acceleration of discovery in chemistry and the life sciences. Lhasa software aids in regulatory submission and helps scientists to work more efficiently and effectively, expediting development.
Lhasa is also involved in a variety of collaborative initiatives. Find out more using the links below.
Lhasa Symposia
Lhasa Symposia offer an excellent opportunity for member representatives to join with Lhasa Limited scientists and staff, with the purpose of sharing knowledge and views on scientific issues and Lhasa Limited products.
Each Lhasa Symposium will focus on a different scientific area relevant to the industry at that time.
Your complete solution for the ICH M7 Guidelines
Lhasa Limited can help you to organise the relevant information for an ICH M7 submission. Using the ICH M7 functionality within the Nexus Suite, Derek and Sarah Nexus are brought together to provide the expert rule-based and statistical-based in silico predictions required under ICH M7.
Events see all events
Lhasa Limited regularly attends relevant conferences around the world in order to meet with its members and prospects and to share knowledge and updates. Lhasa also holds its own face-to-face and virtual events.
Publications see all publications
Lhasa Limited frequently publishes articles, posters and presentations into its library to ensure its members and prospects are kept up-to-date with research and developments.
-
Case study on the use of integrated approaches to testing and assessment for the prediction of a 90-day repeated dose toxicity study (OECD 408) for 2-Ethylbutyric acid using a read-across approach from other branched carboxylic acids.
March 2021
-
Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data
March 2021
-
2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recording
February 2021
-
Bringing Together Scientific Disciplines for Collaborative Undertakings: A Vision for Advancing the Adverse Outcome Pathway Framework
February 2021
News see all news
For recent News and Press Releases from Lhasa Limited, visit our News library.
-
Lhasa Limited releases new data to its Nitrites in Excipients project users
Dec 15 2020
-
Lhasa Limited releases new data to its Aromatic Amines project users
Nov 26 2020
-
Lhasa Limited announces the release of Effiris 2.1; An enhanced qualitative model suite for predicting secondary pharmacology effects.
Nov 23 2020
-
Lhasa Limited releases new data to its Elemental Impurities users
Nov 19 2020
-
Lhasa Limited releases new data sharing initiative: Nitrites in Excipients
Nov 10 2020
-
Lhasa Limited releases Zeneth 8: A faster, more intuitive degradation prediction system
Oct 14 2020
About LHASA
We accelerate the discovery pipeline of the life sciences industry by enabling scientifically robust decisions to be made faster through advanced analytics which are informed by our position as the industry’s honest broker.
Our technology is uniquely designed by scientists, for scientists, and is developed in collaboration with industry stakeholders and regulators. Our not-for-profit status ensures that our sole focus is helping our members to be successful and thereby delivering public benefit.
Useful links
Staff Profiles
Find out more about our talented staff.
Current Vacancies
Want to work for Lhasa? Check out our careers page.
How to find us
Find out how to get to Lhasa's offices.
What are Lhasa Symposia?
Find out more about Lhasa's Symposia.
